STOCK TITAN
  1. Home
  2. Sec-filings
  3. CME
  4. [Form 4] CME GROUP INC. Insider Trading Activity

CME (CME) chief gets 7,076-share award, surrenders 3,135 shares for tax

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

CME Group Inc. Chief Transformation Officer Ken Vroman reported routine equity compensation activity. He acquired 7,076 shares of Class A common stock valued at $311.40 per share through the vesting of performance shares granted in 2022 under CME Group's Omnibus Stock Plan.

On the same date, 3,135 shares at $311.40 per share were surrendered back to the company to cover tax withholding obligations related to this award, rather than sold on the open market. Following these transactions, Vroman directly holds 18,851 shares of CME Group Class A common stock.

Positive

  • None.

Negative

  • None.
Insider Vroman Ken
Role Chief Transformation Officer
Type Security Shares Price Value
Grant/Award Common Stock Class A 7,076 $311.40 $2.20M
Tax Withholding Common Stock Class A 3,135 $311.40 $976K
Holdings After Transaction: Common Stock Class A — 21,986 shares (Direct)
Footnotes (1)
  1. Represents the vesting of performance shares granted in 2022 under CME Group's Omnibus Stock Plan. The number of shares was determined based on the company's achievement of total shareholder return relative to the S&P 500 measured over a three-year performance period from January 1, 2023 through December 31, 2025. Mr. Vroman surrendered shares to the company in order to fulfill tax withholding obligations related to the receipt of the performance share award.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Vroman Ken
(Last) (First) (Middle)
20 S. WACKER DRIVE
(Street)
CHICAGO IL 60606
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Transformation Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock Class A 03/15/2026 A 7,076(1) A $311.4 21,986 D
Common Stock Class A 03/15/2026 F 3,135(2) D $311.4 18,851 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the vesting of performance shares granted in 2022 under CME Group's Omnibus Stock Plan. The number of shares was determined based on the company's achievement of total shareholder return relative to the S&P 500 measured over a three-year performance period from January 1, 2023 through December 31, 2025.
2. Mr. Vroman surrendered shares to the company in order to fulfill tax withholding obligations related to the receipt of the performance share award.
Remarks:
By: Margaret Austin Wright For: Kendal L. Vroman 03/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did CME (CME) executive Ken Vroman report?

Ken Vroman reported vesting of 7,076 CME Class A shares as a performance-based equity award, plus surrender of 3,135 shares to cover tax withholding. These are compensation-related transactions, not open-market buying or selling activity.

Were Ken Vroman’s CME (CME) share movements open-market purchases or sales?

No, the filing shows no open-market purchases or sales. Vroman received 7,076 shares via vesting of performance shares and surrendered 3,135 shares back to the company solely to satisfy tax withholding obligations on that award.

What is the origin of the 7,076 CME shares received by Ken Vroman?

The 7,076 shares represent the vesting of performance shares granted in 2022 under CME Group's Omnibus Stock Plan. The payout was based on CME’s total shareholder return versus the S&P 500 over a three-year period ending December 31, 2025.

Why did Ken Vroman surrender 3,135 CME shares in this Form 4 filing?

He surrendered 3,135 shares to CME Group to fulfill tax withholding obligations tied to the vested performance share award. This “F” code transaction is a tax-withholding disposition and does not reflect a discretionary sale into the market.

How many CME shares does Ken Vroman hold after these reported transactions?

After the reported vesting and tax-withholding surrender, Ken Vroman directly holds 18,851 shares of CME Group Class A common stock. This figure reflects his updated ownership following the March 15, 2026 equity compensation events.

What performance period determined Ken Vroman’s CME performance share vesting?

The performance shares vested based on CME Group’s total shareholder return relative to the S&P 500, measured over a three-year period from January 1, 2023 through December 31, 2025. This relative-return test determined the number of shares ultimately delivered.